Nektar Therapeutics (NKTR) Revenue & Revenue Breakdown
Nektar Therapeutics Revenue Highlights
Latest Revenue (Y)
$98.43M
Latest Revenue (Q)
$24.12M
Main Segment (Y)
Non Cash Royalty Revenue Related To Sale Of Future Royalties
Main Geography (Y)
Non-US
Nektar Therapeutics Revenue by Period
Nektar Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $98.43M | 9.22% |
| 2023-12-31 | $90.12M | -2.10% |
| 2022-12-31 | $92.06M | -9.67% |
| 2021-12-31 | $101.91M | -33.36% |
| 2020-12-31 | $152.91M | 33.41% |
| 2019-12-31 | $114.62M | -90.40% |
| 2018-12-31 | $1.19B | 287.81% |
| 2017-12-31 | $307.71M | 86.00% |
| 2016-12-31 | $165.44M | -28.32% |
| 2015-12-31 | $230.78M | 14.99% |
| 2014-12-31 | $200.71M | 34.77% |
| 2013-12-31 | $148.92M | 83.42% |
| 2012-12-31 | $81.19M | 13.59% |
| 2011-12-31 | $71.48M | -55.06% |
| 2010-12-31 | $159.04M | 121.10% |
| 2009-12-31 | $71.93M | -20.24% |
| 2008-12-31 | $90.19M | -66.97% |
| 2007-12-31 | $273.03M | 25.40% |
| 2006-12-31 | $217.72M | 72.41% |
| 2005-12-31 | $126.28M | 10.51% |
| 2004-12-31 | $114.27M | 7.54% |
| 2003-12-31 | $106.26M | 12.03% |
| 2002-12-31 | $94.84M | 22.43% |
| 2001-12-31 | $77.47M | 50.05% |
| 2000-12-31 | $51.63M | 24.83% |
| 1999-12-31 | $41.36M | 89.76% |
| 1998-12-31 | $21.80M | 34.13% |
| 1997-12-31 | $16.25M | 135.49% |
| 1996-12-31 | $6.90M | 102.94% |
| 1995-12-31 | $3.40M | 100.00% |
| 1994-12-31 | $1.70M | - |
Nektar Therapeutics generated $98.43M in revenue during NA 2024, up 9.22% compared to the previous quarter, and up 85.87% compared to the same period a year ago.
Nektar Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $24.12M | 2.70% |
| 2024-06-30 | $23.49M | 8.55% |
| 2024-03-31 | $21.64M | -9.40% |
| 2023-12-31 | $23.89M | -1.07% |
| 2023-09-30 | $24.14M | 17.78% |
| 2023-06-30 | $20.50M | -5.07% |
| 2023-03-31 | $21.59M | -1.95% |
| 2022-12-31 | $22.02M | -6.78% |
| 2022-09-30 | $23.63M | 9.45% |
| 2022-06-30 | $21.59M | -13.04% |
| 2022-03-31 | $24.82M | -0.75% |
| 2021-12-31 | $25.01M | 0.35% |
| 2021-09-30 | $24.92M | -12.03% |
| 2021-06-30 | $28.33M | 19.80% |
| 2021-03-31 | $23.65M | 0.79% |
| 2020-12-31 | $23.46M | -21.88% |
| 2020-09-30 | $30.03M | -38.52% |
| 2020-06-30 | $48.85M | -3.41% |
| 2020-03-31 | $50.57M | 49.35% |
| 2019-12-31 | $33.86M | 15.89% |
| 2019-09-30 | $29.22M | 25.32% |
| 2019-06-30 | $23.32M | -17.39% |
| 2019-03-31 | $28.22M | -29.14% |
| 2018-12-31 | $39.83M | 43.46% |
| 2018-09-30 | $27.76M | -97.45% |
| 2018-06-30 | $1.09B | 2761.06% |
| 2018-03-31 | $38.02M | -60.18% |
| 2017-12-31 | $95.47M | -37.57% |
| 2017-09-30 | $152.93M | 342.13% |
| 2017-06-30 | $34.59M | 39.88% |
| 2017-03-31 | $24.73M | -33.97% |
| 2016-12-31 | $37.45M | 3.07% |
| 2016-09-30 | $36.34M | 10.89% |
| 2016-06-30 | $32.77M | -44.35% |
| 2016-03-31 | $58.88M | 49.56% |
| 2015-12-31 | $39.37M | -34.33% |
| 2015-09-30 | $59.95M | 164.56% |
| 2015-06-30 | $22.66M | -79.17% |
| 2015-03-31 | $108.80M | 456.47% |
| 2014-12-31 | $19.55M | -85.28% |
| 2014-09-30 | $132.87M | 366.00% |
| 2014-06-30 | $28.51M | 44.22% |
| 2014-03-31 | $19.77M | -36.52% |
| 2013-12-31 | $31.15M | -48.86% |
| 2013-09-30 | $60.91M | 79.87% |
| 2013-06-30 | $33.86M | 47.20% |
| 2013-03-31 | $23.00M | 8.79% |
| 2012-12-31 | $21.15M | 14.85% |
| 2012-09-30 | $18.41M | -22.26% |
| 2012-06-30 | $23.68M | 31.95% |
| 2012-03-31 | $17.95M | 13.73% |
| 2011-12-31 | $15.78M | -41.69% |
| 2011-09-30 | $27.07M | 56.18% |
| 2011-06-30 | $17.33M | 53.39% |
| 2011-03-31 | $11.30M | -75.07% |
| 2010-12-31 | $45.31M | 19.48% |
| 2010-09-30 | $37.92M | -10.90% |
| 2010-06-30 | $42.56M | 28.06% |
| 2010-03-31 | $33.24M | -14.80% |
| 2009-12-31 | $39.01M | 281.58% |
| 2009-09-30 | $10.22M | -21.29% |
| 2009-06-30 | $12.99M | 33.75% |
| 2009-03-31 | $9.71M | -65.75% |
| 2008-12-31 | $28.35M | 32.25% |
| 2008-09-30 | $21.44M | 5.09% |
| 2008-06-30 | $20.40M | 2.05% |
| 2008-03-31 | $19.99M | -69.60% |
| 2007-12-31 | $65.77M | - |
Nektar Therapeutics generated $24.12M in revenue during Q3 2024, up 2.70% compared to the previous quarter, and up 117.68% compared to the same period a year ago.
Nektar Therapeutics Revenue Breakdown
Nektar Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Non Cash Royalty Revenue Related To Sale Of Future Royalties | $64.27M | $68.92M | $69.79M | $77.75M | $48.56M |
| Product | $33.56M | $20.68M | $20.35M | $23.73M | $17.50M |
| License Collaboration And Other Revenue | $597.00K | $520.00K | $1.91M | $436.00K | $55.85M |
| Royalty | - | - | - | - | $31.00M |
Nektar Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Non Cash Royalty Revenue Related To Sale Of Future Royalties (65.29%), Product (34.10%), and License Collaboration And Other Revenue (0.61%).
Quarterly Revenue by Product
| Product/Service | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $19.51M | $8.02M | $6.03M | $5.48M | $5.82M | $4.66M | $4.72M | $4.38M | $4.97M | $5.31M | $5.69M | $5.89M | $5.19M | $7.85M | $4.79M | $2.88M | $5.69M | $5.49M | $3.44M | $5.82M |
| License Collaboration And Other Revenue | $122.00K | $378.00K | $97.00K | $341.00K | $155.00K | $9.00K | $15.00K | $17.00K | $314.00K | $9.00K | $1.57M | $40.00K | $314.00K | $28.00K | $54.00K | $428.00K | $1.63M | $26.27M | $27.52M | $7.12M |
| Non Cash Royalty Revenue Related To Sale Of Future Royalties | $33.03M | $15.73M | $15.51M | $18.06M | $18.17M | $15.83M | $16.86M | $17.63M | $18.34M | $16.26M | $17.56M | $19.08M | $19.41M | $20.46M | $18.80M | $20.56M | $10.42M | $7.68M | $9.89M | $8.72M |
| Royalty | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-412.00K | $12.29M | $9.40M | $9.72M | $12.21M |
Nektar Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Non Cash Royalty Revenue Related To Sale Of Future Royalties (62.71%), Product (37.05%), and License Collaboration And Other Revenue (0.23%).
Nektar Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Non-US | $97.05M | $78.64M | $82.21M | $91.79M | $87.95M |
| UNITED STATES | $1.38M | $11.48M | $9.84M | $10.11M | $64.97M |
Nektar Therapeutics's latest annual revenue breakdown by geography, as of Dec 24: Non-US (98.60%), and UNITED STATES (1.40%).